Otonomy, Inc.
6275 Nancy Ridge Drive
Suite 100
San Diego
California
92121
United States
Tel: 858-242-5200
Fax: 858-200-0933
Website: http://www.otonomy.com/
Email: info@otonomy.com
About Otonomy, Inc.
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address diseases of the inner and middle ear. There are no drugs currently approved by the FDA for the lead indications we are currently pursuing for our product candidates. Our lead candidate AuriPro completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and we have submitted a request to the FDA for approval. If approved, we anticipate a commercial launch in early 2016 and are building our business and commercial team to meet the needs of this next stage of our growth.
97 articles with Otonomy, Inc.
-
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
5/2/2019
Glenmark Therapeutics Inc., USA announced a co-promotion agreement with Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology.
-
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
11/6/2018
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic
-
Otonomy Provides Corporate and Product Pipeline Update - Jan. 9, 2018
1/9/2018
The company provided an update on its product pipeline and financial guidance today.
-
Otonomy said dropping the program and terminating the employees will provide a cash savings of more than $20M in 2018.
-
The company plans to meet with FDA to discuss results and clinical requirements for registration.
-
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/9/2017
Conference call and webcast today at 4:30 p.m. EST
-
Otonomy Slashes 33% of Staff After Failed Phase III Clinical Trial for Meniere’s Disease
9/14/2017
-
Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges
8/31/2017
-
Otonomy Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/4/2017
-
Otonomy To Report Second Quarter 2017 Financial Results And Provide Corporate Update
7/27/2017
-
Otonomy Announces FDA Acceptance Of OTIPRIO Supplemental New Drug Application Filing For Acute Otitis Externa
7/18/2017
-
Otonomy Announces Successful End-Of-Phase II Review By FDA For OTIPRIO In Acute Otitis Media With Tympanostomy Tubes
6/22/2017
-
Otonomy To Host Key Opinion Leader Meeting For Investors On Ménière's Disease
6/20/2017
-
Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update
5/5/2017
-
Otonomy To Report First Quarter 2017 Financial Results And Provide Corporate Update
4/28/2017
-
Otonomy Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
3/3/2017
-
Otonomy To Report Fourth Quarter And Full Year 2016 Financial Results And Provide Corporate Update
2/24/2017
-
Otonomy Release: Company Initiates Patient Enrollment In Phase II Clinical Trial Of OTO-104 As Protectant Against Cisplatin-Induced Hearing Loss
1/19/2017
-
Otonomy Provides Corporate And Product Pipeline Update
1/9/2017
-
Otonomy Announces Positive Top-Line Results From Phase III Clinical Trial of OTIPRIO in Patients With Acute Otitis Externa
1/5/2017